| Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion. | |
| | |
MedLine Citation:
|
PMID: 20579545 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: We examined the effects of the flavanol (-)-epicatechin on short- and long-term infarct size and left ventricular (LV) structure and function after permanent coronary occlusion (PCO) and the potential involvement of the protective protein kinase B (AKT)/extracellular signal-related kinase (ERK) signaling pathways. BACKGROUND: (-)-epicatechin reduces blood pressure in hypertensive patients and limits infarct size in animal models of myocardial ischemia-reperfusion injury. However, nothing is known about its effects on infarction after PCO. METHODS: (-)-epicatechin (1 mg/kg daily) treatment was administered via oral gavage to 250 g male rats for 10 days before PCO and was continued afterward. The PCO controls received water. Sham animals underwent thoracotomy and treatment in the absence of PCO. Immunoblots assessed AKT/ERK involvement 2 h after PCO. The LV morphometric features and function were measured 48 h and 3 weeks after PCO. RESULTS: In the 48-h group, treatment reduced infarct size by 52%. There were no differences in hemodynamics among the different groups (heart rate and aortic and LV pressures). Western blots revealed no differences in AKT or ERK phosphorylation levels. At 3 weeks, PCO control animals demonstrated significant increases in LV end-diastolic pressure, heart and body weight, and LV chamber diameter versus sham. The PCO plus (-)-epicatechin group values were comparable with those of the sham plus (-)-epicatechin group. Treatment resulted in a 33% decrease in myocardial infarction size. The LV pressure-volume curves demonstrated a right shift in control PCO animals, whereas the (-)-epicatechin curves were comparable with those of the sham group. The LV scar area strains were significantly improved with (-)-epicatechin. CONCLUSIONS: These results demonstrate the unique capacity of (-)-epicatechin to confer cardioprotection in the setting of a severe form of myocardial ischemic injury. Protection is sustained over time and preserves LV structure and function. The cardioprotective mechanism(s) of (-)-epicatechin seem to be unrelated to AKT or ERK activation. (-)-epicatechin warrants further investigation as a cardioprotectant. |
| | |
Authors:
|
Katrina Go Yamazaki; Pam R Taub; Maraliz Barraza-Hidalgo; Maria M Rivas; Alexander C Zambon; Guillermo Ceballos; Francisco J Villarreal |
Related Documents
:
|
1424005 - Effects of dynamic cardiomyoplasty on regional wall motion, ejection fraction, and geom... 9808605 - Electromechanical characterization of chronic myocardial infarction in the canine coron... 3704595 - Echocardiographic assessment of left ventricular function in left ventricular volume lo... 17174235 - Clinical features of isolated ventricular noncompaction in adults long-term clinical co... 11515695 - Myocardial uptake and release of substrates in type ii diabetics undergoing coronary su... 16942455 - A modified postural drainage position produces less cardiovascular stress than a head-d... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 55 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-06-28 Completed Date: 2010-07-20 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 2869-76 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Medicine, University of California, San Diego, La Jolla, California 92093, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Analysis of Variance Animals Catechin / pharmacology* Coronary Circulation Coronary Occlusion / drug therapy*, mortality, radiography Disease Models, Animal Hemodynamics / physiology* Male Myocardial Infarction / drug therapy*, mortality, pathology, prevention & control* Myocardial Reperfusion Injury / prevention & control Probability Random Allocation Rats Rats, Sprague-Dawley Reference Values Survival Rate Treatment Outcome Ventricular Remodeling / drug effects*, physiology |
| Grant Support | |
ID/Acronym/Agency:
|
AT-004277/AT/NCCAM NIH HHS; HL-43617/HL/NHLBI NIH HHS; R01 HL043617-16/HL/NHLBI NIH HHS; R21 AT004277-01A2/AT/NCCAM NIH HHS; R21 AT004277-02S1/AT/NCCAM NIH HHS; T32-HL007444/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
154-23-4/Catechin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiac origins of the postural orthostatic tachycardia syndrome.
Next Document: Aspirin for primary prevention of cardiovascular events in people with diabetes.